Both agents are in Phase III trials with potential availability within the next few years, assuming successful trial completion and regulatory approval
Last reviewed: June 5, 2026 Last updated: June 5, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations
cancer, stroke, proliferation of viruses, and more
Carrying extra weight puts additional strain on the heart and can lead to inflammation that damages blood vessels
The effects of Cagrilintide are usually evaluated through several factors: reduced food intake, fewer cravings, improved appetite control, longer satiety, and gradual weight reduction